Wednesday, August 20, 2014

M Partners starts Antibe Therapeutics at buy

M Partners starts Antibe Therapeutics at buy

August 20, 2014 by · Leave a Comment 

Tweet M Partners has initiated coverage of Antibe Therapeutics (TSX-V:ATE) with a “buy” rating and 12-month price target of $1.30. The stock closed at 50 cents on Tuesday. Antibe Therapeutics is a clinical stage drug development company, with a portfolio of patented anti-inflammatory drug candidates that focus on the non-steroidal anti-inflammatory drugs (NSAIDs) market. The […]

Scientific data supports superiority of Pivotal’s Omega-3 product

Scientific data supports superiority of Pivotal’s Omega-3 product

August 19, 2014 by · Leave a Comment 

Tweet Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) has reported that an article published in the current issue of the scientific journal demonstrates that the sustained endothelial vasodilatory effect of Omega-3 formulations are EPA:DHA ratio and purity dependent and involve predominantly the endothelial nitric oxide synthase derived nitric oxide formation. Pivotal’s 6:1 EPA:DHA formulation of VASCAZEN was shown […]

Gamida Cell in investment pact with Novartis

Gamida Cell in investment pact with Novartis

August 19, 2014 by · Leave a Comment 

Tweet Closely held Gamida Cell of Israel has signed an investment and option agreement with Novartis Pharma AG. Under the accord, Novartis will invest $35-million in Gamida Cell in exchange for a 15% equity interest and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement […]

Leerink starts Immune Design at outperform

Leerink starts Immune Design at outperform

August 18, 2014 by · Leave a Comment 

Tweet Leerink Partners has launched coverage of Immune Design (NASDAQ:IMDZ) with an “outperform” rating and 12-month price target of $25. The stock was quoted at $12.15 near the mid-session on Monday. The company is focused on immunotherapies for cancer, and has two proprietary platforms, ZVex and GLAAS, for activating essential cells of the immune system […]

Leerink starts Intersect ENT at outperform

Leerink starts Intersect ENT at outperform

August 18, 2014 by · Leave a Comment 

Tweet Leerink Partners has launched coverage of Intersect ENT (NASDAQ:XENT) with an “outperform” rating and $20 price target. The stock closed at $15.05 on Friday. “Intersect looks set to deliver a 73% 2013-2016 CAGR (at least), faster than most small-cap MedTech peers, as the company drives higher ear, nose and throat (ENT) use of its […]

WB starts Pfenex at outperform

WB starts Pfenex at outperform

August 18, 2014 by · Leave a Comment 

Tweet William Blair & Co. has initiated coverage of Pfenex (NYSE MKT:PFNX) with an “outperform” rating and “aggressive growth” profile. The stock closed at $6.50 on Friday. “Our bullish outlook is based on our view that the combination of the company’s lead product candidate, technology platform, advancing pipeline, and potential for additional strategic collaborations offers […]

TearLab to unveil second generation tear testing platform

TearLab to unveil second generation tear testing platform

August 14, 2014 by · Leave a Comment 

Tweet At its analyst and investor day on Sept. 23, TearLab (NASDAQ:TEAR; TSX:TLB) plans to cover its current business and growth strategies, international market opportunities recent R&D activities, including development of a second-generation point-of-care tear testing platform. On the second quarter conference call earlier this month, CEO Elias Vamvaskas said most of the research has been […]

Microbix virology revenue up 24% in Q3

Microbix virology revenue up 24% in Q3

August 14, 2014 by · Leave a Comment 

Tweet Fiscal third quarter revenue for Microbix Biosystems (TSX:MBX) was led by a 24% increase in its virology products division, totalling just over $2-million for the quarter ended June 30, 2014, compared with $1.6-million a year earlier. The higher virology products revenue was primarily due to continued growth in customer demand, including significant new business […]

Leerink ups Intra-Cellular price target to $35

Leerink ups Intra-Cellular price target to $35

August 13, 2014 by · Leave a Comment 

Tweet Leerink Partners has raised its price target for “outperform-rated” Intra-Cellular Therapies (NASDAQ:ITCI) to $35 from $34 in assumed coverage. The stock closed at $15.98 on Tuesday. Intra-Cellular has announced that following a successful end of Phase 2 meeting with the FDA, it will conduct two pivotal Phase 3 trials with its ITI-007 drug candidate […]

Avivagen begins female sterilization study for mammals

Avivagen begins female sterilization study for mammals

August 13, 2014 by · Leave a Comment 

Tweet Avivagen (TSX-V:VIV) has started a proof-of-concept study on its optioned technology for the permanent sterilization of female mammals that may eliminate the need for surgical spaying. The invention is a novel and drug-based means of accomplishing this long-standing veterinary goal and could prove effective for companion animal sterilization, control of feral and wild animal […]

Next Page »

Email Newsletters with Constant Contact
Google+